Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
Status:
Unknown status
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
RESULT is a phase II dose-escalating, open-label, safety and efficacy study to determine if
there is a potential benefit of resveratrol in combination with sirolimus in patients with
lymphangioleiomyomatosis (LAM). The primary study objective is to assess the change in serum
vascular endothelial growth factor-D (VEGF-D) level after 24 weeks of treatment with a
combination of resveratrol and sirolimus as compared to the VEGF-D level in patients on a
stable dose of sirolimus alone. The secondary objectives of this study include an assessment
of the safety and adverse effect profile of combined resveratrol and sirolimus in adult
patients with LAM, and to determine the effect of treatment with a combination of resveratrol
and sirolimus on changes in lung function and quality of life.